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1. Introduction 
Prolactin (PRL) is one of several hormones that are produced by the pituitary gland. PRL 
has many different roles throughout the body, and most of those are clearly shown as 
clinical symptom. Perhaps the most important classical role of prolactin is to stimulate milk 
production in women after the delivery of a baby. Prolactin levels increase during 
pregnancy causing the mammary glands to enlarge in preparation for breastfeeding and 
ready to secrete colostrums closely after delivery. Later on the elevated prolactin levels help 
with the sustained production of milk during nursing. The somatomammotrop cells of the 
anterior pituitary gland synthesize and secrete prolactin, which is under the control of 
hypothalamic factors, mainly the tonic inhibition of Dopamine (DA). There are several other 
sources of PRL-like substances in the periphery such as placental lactogens, (similar to 
pituitary PRL), mammary gland (produced within the mammary epithelial cells), or PRL 
variants of immune cell origin (that modulates the immune system). (Gellersen,1989; 
Andersen 1990; Lkhider, 1996; Kurtz,1993; Gala, 1994, Montgomery,1990; Ben-Jonathan 
1996; Yu-Lee LY 1997) 
It is important to underline that serum PRL in normal individuals is considered as almost 
entirely pituitary PRL sources, the above mentioned extra pituitary-PRL may contribute 
significant amounts but either carries as specific function and target mainly to the local 
environment acting via paracrine/autocrine manner. (Yu-lee 1997; Bachelot 2007) 
During the first several months of breastfeeding, the higher basal prolactin levels also serve 
to suppress ovarian cyclicity , through the inhibition of pituitary hormones, mainly via LH 
suppression (Taya 1982) This is the reason why women who are breastfeeding do not get 
their periods and therefore do not often become pregnant. In actively breastfeeding mothers 
the related hyperprolactinaemia persisting even over a year. It was observed that extended 
lactational amenorrhea is associated with low LH levels, and interestingly suckling induced 
PRL elevation as a response has a positive effect on prolongation. (Diaz 1991; Diaz 1995). 
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Menstruation and ovulation may only occasionally occur before the drop of elevated basal 
PRL levels. As time goes on with less frequent breastfeeding, e.g. during weaning however, 
the PRL levels do not stay as high and the woman may start to ovulate. In cases of 
nonlactating/ nonbreastfeeding mothers, that may happen between 2-3 month after delivery. 
(Baird 1979) 
Similarly, elevated PRL levels are shown during gestation, but mechanisms to inhibit 
ovulation is related to elevated estardiol and progesterone levels and a consequent 
depression of pituitary FSH secretion (Marrs 1981). 
Generally, the lactogenic hormones play role also in regulation of reproductive function. On 
one hand, PRL is essential to maintain regular oestrus cycles. PRL knock out mice are 
completely infertile (Horsemann 1997). One of the other actions of PRL is to stimulate 
ovarian production of progesterone. That is required in the process of preparation for 
embryo implantation and it is dependent on a continued estrogen and progesterone 
secretion by the corpus luteum, which is supported by a functional pituitary during the first 
half of pregnancy in rodents. (Binart 2000)  
On the other hand, high prolactin levels are associated with anovulation or may 
cause directly or indirectly infertility. In young women, hyperprolactinemia is probably one 
of the most common endocrine disorders related to pituitary function. Women who are not 
pregnant and are not breastfeeding should have lower levels of basal PRL (typically 10–28 
μg/L in women and 5–10 μg/L in men are defined as “normal levels”) If a non-pregnant 
woman has abnormally high levels of PRL, it may cause her difficulty in becoming 
pregnant. It is considered as the most frequent cause of anovulatory sterility, although 
spontaneous pregnancy may occur occasionally. The prevalence of hyperprolactinemia 
varies in different patient populations, stays below 1% (0.4% in an unselected normal 
population) but can be as high as 17% of women with reproductive disorders shown at the 
clinics (Crosignani 1999) 
The suppression of pituitary hormones by PRL, similar that described during lactation has 
an indirect anovulatory effect. PRL however, acts also directly on the ovary to inhibit the 
hCG-induced follicle rupture, resulting in the inhibition of ovulation. (Yoshimura 1989).  
Clinically significant elevation of PRL levels may cause infertility in several different ways. 
First, prolactin may stop a woman from ovulating. If this occurs, a woman’s menstrual 
cycles will stop. In less severe cases, high prolactin levels may only disrupt ovulation once 
in a while. This would result in intermittent ovulation or ovulation that takes a long time to 
occur. Women in this category may experience infrequent or irregular periods. Women with 
the mildest cases involving high prolactin levels may ovulate regularly but not produce 
enough of the hormone progesterone after ovulation. This is known as a luteal phase defect. 
Deficiency in the amount of progesterone produced after ovulation may result in a uterine 
lining that is less able to have an embryo implant. Some women with this problem may see 
their period come a short time after ovulation (Shibli-Rahhal,2011) 
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Hyperprolactinemia is commonly found in both female and male patients with abnormal 
sexual and/or reproductive function or with galactorrhea. If serum prolactin levels are above 
200 μg/L, a prolactin-secreting pituitary adenoma (prolactinoma) is the underlying cause, 
but if levels are lower, differential diagnoses include the intake of various drugs, 
compression of the pituitary stalk by other pathology, hypothyroidism, renal failure, 
cirrhosis, chest wall lesions, or idiopathic hyperprolactinemia. When a pituitary tumour is 
present, patients often have pressure symptoms in addition to endocrine dysfunction, such 
as headaches, visual field defects, or cranial nerve deficits (Wang, 2012). The objectives of 
therapy are to improve the symptoms associated with high PRL levels and to reduce the size 
of a pituitary tumour.  
Pharmacotherapy is available to reduce the tumour size and consequently decrease PRL 
levels. The large majority of patients with prolactinomas, both micro- and 
macroprolactinomas, can be successfully treated with dopamine D2 receptor agonists as 
first-line treatment, with normalization of prolactin secretion and gonadal function, and 
with significant tumour shrinkage in a high percentage of cases, to prevent the need for 
surgery. In cases when the only cause of infertility is chronic anovulation due to 
hyperprolactinemia, a 60-80% pregnancy rate can be achieved. Surgical resection of the 
prolactinoma is the option for patients who may refuse or do not respond to long-term 
pharmacological therapy. Radiotherapy and/or estrogens are also reasonable choices if 
surgery fails. In patients with asymptomatic microprolactinoma no treatment needs to be 
given and a regular follow-up with serial prolactin measurements and pituitary imaging 
should be organized (Asa 2002; Crosignani 1999, Molitch 2003). 
The most commonly used dopamine agonists are bromocriptine, pergolide, quinagolide and 
cabergoline. When comparing the plasma half-life, efficacy and tolerability of these drugs 
are different, there is also important to evaluate the risk/ benefits profile of each product. As 
the current clinical practice, pharmacological treatment with dopamine agonist plays an 
important role. The recommendations on the most effective dosages and the advantages of a 
long term efficacy of products have been evaluated summarizing the results of case histories 
of the last decades. 
2. Clinical diagnosis of hyperprolactinemia 
A variety of etiological factors including disorders of the hypothalamo-pituitary axis, 
interruption of dopamine synthesis, stress, pituitary tumours, polycystic ovary syndrome, 
primary hypothyroidism, and various medications may lead to hyperprolactinemia (5). 
Hyperprolactinemia in girls causes delayed puberty, hypogonadotropic hypogonadism, 
primary or secondary amenorrhea, and galactorrhea (Fideleff, 2000). Hyperprolactinemia in 
men may result in as a first signs of decreased libido or impotence, however also cause 
inefficient sperm production and infertility (Colao, 2004). 
As one of the fist signs in women with high prolactin levels may have irregular periods or 
no periods at all. Another common symptom is “galactorrhea”, which is the occurrence of a 
milky discharge from the breast in a woman who has not recently been pregnant. The 
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discharge is the result of persistant high PRL levels stimulating the mammary gland for milk 
production. Some women may see galactorrhea occur spontaneously. Others may see it only 
if they squeeze their nipples.  
As diagnostic practice, after signs and labtests have been evaluated the magnetic resonance 
imaging (MRI) of the pituitary gland should be performed in all patients. A pituitary 
adenoma with a diameter of less than 1 cm is defined as “microadenoma” and one above 1 
cm in diameter as “macroadenoma”.  
3. Measurement of prolactin 
Prolactin can be measured with a simple blood test drawn at the fertility doctor's office. In 
order to get accurate results, prolactin should be drawn first thing in the morning. Since PRL 
may serve as a hormone to affect reproductive functions, sexual contact, stimulation of 
nipples in human may cause a not just immediate but also next-day-long alterations of the 
PRL secretory pattern. (Kruger 2012) These fluctuations are measured on the next day to 
produce a PRL elevation around noon, additional of the regular circadian rhythm of PRL 
levels, as the peak on the morning. Accordingly it is important to note that the woman 
should have the instructions to eat nothing from the night before and to avoid any 
stimulation of the breast and nipples, included sexual intercourse as well, from the day 
before also. 
Since stimulation of the breast /nipples (stress such as physical exam) may cause immediate 
release of PRL one common mistake that doctors make is to draw a prolactin blood test 
immediately after a patient has had a breast exam in the office. These women will have high 
prolactin levels because of the exam and therefore they may show false (i.e. transient) 
increase of PRL levels. Prolactin should also be drawn early in the menstrual cycle - before 
ovulation. This is because prolactin levels are naturally higher after ovulation. 
A prolactin level of 5-20 ng/mL is considered normal in both sexes, according to some 
laboratories and test references the male and female (a bit higher) normal range may differ. 
A level above 20 ng/mL in two successive measurements is defined as hyperprolactinemia 
(7). According to WHO standards: 1 μg/L = 21.2 mIU/L. PRL levels > 250 ng/mL usually 
indication for prolactinoma, when PRL > 500 ng/mL it is considered as diagnosis for 
macroprolactinoma. (Melmed, 2011) 
There are cases when false positive and elevated PRL levels are measured: two high 
molecular mass forms of prolactin (PRL) in serum have been identified: macroprolactin (big-
big PRL, > 100 kDa) and big PRL (40-60 kDa). Big PRL is a consistent “normal” component 
of total serum PRL but rarely cause of hyperprolactinemia. Macroprolactin is usually a 
complex of PRL and IgG in composition, it is formed in the circulation from monomeric PRL 
with a molecular mass of 150-170 kDa, but may have some additional variability in 
composition. In labor tests the PRL in the complex remains reactive to a variable extent in 
immunoassays. Individuals may show a different pattern of % of these variants, or even can 
be a predominant immunoreactive component of circulating PRL and the cause of apparent 
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hyperprolactinemia, but it has minimal bioactivity in vivo and is not of pathological 
significance. As necessary the reference technique of gel filtration chromatography at the 
laboratory should be available for confirmation and request on investigation of samples to 
avoid confusion of diagnostics. (Fahie-Wilson 2005) 
4. Causes of high prolactin levels  
4.1. Pituitary tumours  
Pituitary adenomas are the most common tumour type in the pituitary gland. There is 
approximately 10% incidence was shown obtained by post-mortem autopsy, with similar 
ratio of male and female patients. The most frequently detected tumours (over 39%) are 
sparsely granulated PRL cell adenomas. The others types are GH cell or mixed PRL/GH 
adenoma, ACTH cell adenoma/Crooke’s cell adenoma (~14%) ; Gonadotroph cell adenoma 
(6.6%); Null cell adenoma/oncocytoma (~32%) and other or unclassified types (Buurman, 
2006).  
Invasive tumours with multiple recurrences are only classified as aggressive tumours or 
"atypical adenomas". Tumours with systemic metastasis must be considered as carcinomas, 
and “only” make up 0.1% to 0.2% of all pituitary tumours, but with very poor prognostics of 
66% mortality (Oh, 2012). However it was suggested that a full picture inlcuded clinical 
signs (gender, DA-resistant hyperprolactinemia, etc) , radiological status (invasive macro or 
giant tumour) and histological signs of angiogenesis, mitoses level, vascular invasion and 
molcular biology parameters (Ki-67 > 3 %, p53 positive, up-regulation of genes related to 
invasion and proliferation, and allelic loss of chromosome 11) should be taken into account 
considering the potential malignancy, prognosis of prolactin secreting tumours and identify 
the optimal therapy as early as possible. The key question is to identify factors associated 
with tumour aggressiveness. The approach combined genomic and transcriptomic analysis 
focus to the subtype of pituitary tumour able to identify molecular events associated with 
the aggressive and malignant phenotypes. Allelic loss in certain loci of chromosome 11 has 
been detected in tumours with signs of malignancy, potentially responsible for triggering 
the aggressive and malignant phenotypes. Within the recent years there are an increasing 
number of genes or molecular signs that has been associated with pituitary tumorigenesis to 
develop predictive and potential prognostic markers. (Zemmoura, 2012; Dworakowska, 
2012; Wierinckx 2011)  
About one-third of all pituitary tumours are not associated with hypersecretory syndromes 
but, rather, present with symptoms of an intracranial mass, such as headaches, nausea, 
vomiting or visual field disturbances. Only rare cases of pituitary tumours are considered as 
malignant prolactinoma. Tumours that produce growth hormone (GH) may also secrete 
prolactin in nearly 25% of cases. This is a common source of misdiagnosis, as the features of 
prolactin excess may capture attention while the more subtle features of GH excess go 
unnoticed. 
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4.1.1. Characteristics of pituitary adenomas 
In some people, a small group of cells may form a cyst in the pituitary gland which 
produces elevated levels of prolactin. These cysts are called prolactinomas or pituitary 
adenomas. It is unclear exactly how these cysts get started. Recent investigations on 
pituitary tumours reported that approximately 12% of pituitary glands (obtained by autopsy 
of 3048 patients) are shown histologically diagnosed but clinically inapparent adenoma. 
Among the mean tumour size is approx 1.9mm. According to published data two-thirds of 
adenomas has a tumour size <3 mm, half of them were smaller than 1 mm in diameter and 
~23% was between 3-10mm. In this study only few (3/76) tumours were identified as 
macroadenomas corresponding to a tumour size >10 mm. (Buurman, 2006)  
The prevalence of clinically apparent prolactinomas ranges from 6–50/ 100,000 in reported 
populations (Daly, 2006; Fernandez 2010). The prevalence of “ever-treated“ 
hyperprolactinemia is approximately 20 /100,000 in male patients and approximately 90 
/100,000 in female patients. (Kars, 2009) 
The adenomas can be seen and measured using MRI and classified based on their size.  
Small adenomas are known as microadenomas. They measure less than one centimetre in 
diameter. This is the most common type of adenoma found. Microadenomas can even be 
present in healthy people who do not have high prolactin levels. Microadenomas can be 
treated with medication. They do not grow large and do not need to be treated if hormone 
levels are normal. Microprolactinomas usually follow a benign course and rarely progress to 
macroprolactinomas. However, in rare cases microadenoma may transform to other 
tumours. 
 A case history it was reported that a microadenoma transformed to macroprolactinoma 
within 10 month, probably due to estrogen therapy applied. The case report emphasizes 
the role of dopaminergic agonist in treatment of hyperprolactinemia. (Garcia, 1995) 
 A case history of a 22 -year-old woman with the signs of galactorrhea and slight 
hyperprolactinemia , showed 7-mm intrapituitary lesion which responded to treatment 
with cabergoline. This PRL-secreting microadenoma has a sudden change within 4 
years of diagnose. The case represents a rapid evolution from a microprolactinoma 
initially responding to dopamine agonists to a fatal pituitary carcinoma. 
(Guastamacchia, 2007) 
Adenomas larger than 1 centimetre are called macroadenomas. If untreated, 
macroadenomas can grow further and start to compress the nearby tissues and structures 
causing life-threatening events or even fatal outcome. The closest structures are the optic 
nerves, internal carotid arteries. If a macroadenoma causes compression of the optic nerves, 
partial blindness can result. For this reason, it is important to treat macroadenomas whether 
or not a woman is interested in getting pregnant. Medication can be used to treat them but if 
that fails, surgery may be necessary. 
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 According to a recent clinical study in Japan, treatment with Cabergoline achieved a 
high pregnancy rate with uneventful outcomes in infertile women with prolactinoma, 
independent of tumour size and bromocriptine resistance or intolerance. Over 90% of 
patients in the study conceived pregnancies, and one-third of the macroprolactinomas 
disappeared. Cabergoline monotherapy could serve as an alternative of the conventional 
combination bromocriptine therapy with surgery or irradiation in macroprolactinomas. 
(Ono, 2010) 
4.2. Hypothyroidism  
The hyperprolactinemia of hypothyroidism is related to several mechanisms. In response to 
the hypothyroid state, a compensatory increase in the discharge of central hypothalamic 
thyrotropin releasing hormone (TRH) results in increased stimulation of prolactin secretion. 
Although TRH was originally named for its ability to trigger the release of thyroid-
stimulating hormone (TSH) in mammals, it became apparent that TRH exerts multiple 
hypophysiotropic activities also in human. Stimulation with TRH will provide a diagnostic 
test to demonstrate a TSH release curve typical of the subclinic hypothyroidism. PRL is 
under tonic inhibition by the hypothalamus by way of the PRL inhibitory factor, DA. PRL-
releasing factors include TRH., Increased release of TRH may also cause a sustained 
stimulation of prolactin release from the pituitary gland. There are several clinical reports 
presented the correlation between subclinic hypothyroidism-hyperprolactinemia and 
sterility. Treatment with thyroid hormone supplements will result in correction of both the 
thyroid feedback and the high prolactin levels.  
4.3. Macroprolactinemia 
Asymptomatic patients with intact gonadal and reproductive function and moderately 
elevated prolactin levels may have macroprolactinemia (Vallette-Kasic, 2002). 
Hypersecretion of PRL by lactotroph cells of the anterior pituitary cause 
hyperprolactinemia. Patients with hyperprolactinemia may have radiologically undetected 
microprolactinomas, but some of them may present other causes of hyperprolactinemia 
characterised as a symptom of macroprolactinemia, with a predominance of higher 
molecular mass prolactin forms (big-big prolactin, MW > 150 kDa). This term should not be 
confused with macroprolactinoma, which refers to a large pituitary tumour greater than 10 
mm in diameter. 
The prevalence of macroprolactinemia varies between 15-46% in hyperprolactinemic 
populations, and it may because confusing tests results that could not be differentiated from 
true hyperprolactinemic patients, on the basis of clinical features alone. The 
pathophysiology of macroprolactinemia is based on a mechanisms of the increased 
antigenicity of these molecules, leading to the appearance of autoantibodies against PRL, 
which can consequently reduce the bioactivity of PRL and provide extended half-life. 
Therefore macroprolactinemia is manifested with less frequent clinical symptoms in 
macroprolactinemic patients and the tests results mainly due to the delayed clearance of 
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PRL. According to recent publications of Isik et al, evaluating over 300 hyperprolactinemic 
patients, over 26% of them resulted in elevated macroprolactin levels, with the less frequent 
signs of galactorrhea or abnormal MRI results compared those to patients with predominant 
monomer hyperprolactinemia. The other symptoms and frequency of amenorrhea, 
infertility, irregular menses, gynecomastia, and erectile dysfunction were similar in both 
groups. (Isik, 2012) 
Macroprolactinemic patients have no clinical symptoms of hyperprolactinemia and may 
have no pituitary adenomas. It is still controversial whether macroprolactinemia is a benign 
condition that does not need further investigation and treatment. Patients can be screened 
for macroprolactinemia by PEG (polyethylene glycol) precipitation as a standard laboratory 
test with a results of recovery of ≤40% to normal monomeric PRL level is used as an 
indication of macroprolactinemia (Tamer, 2012). The clinical importance of this test is based 
on the lower prevalence of pituitary adenomas in this group, compared to “true 
hyperprolactinemic” patients. 
4.4. PCOS (polycystic ovary syndrome)  
PCOS is a common problem that can cause infertility by inhibiting ovulation, affecting 3.5-
10% of the reproductive age of women. For unknown reasons, some women with PCOS 
may have slightly high PRL levels. PCOS similar to hypoprolactinemic are both common 
causes of secondary amenorrhoea in women. The relationship between PCOS and 
hyperprolactinemia so far has been reported still with controversial results: it seems that 
PCOS is very prevalent with hyperprolactinemia, nevertheless there are different reasons of 
altered regulation of gondotropin secretion, and suggests that these conditions have 
independent origins. Recent investigators using serial serum sampling have excluded 
transient elevations of PRL and have shown a less frequent association of these two 
disorders. According to clinical guidelines PCOS patients with increased PRL levels must be 
investigated for other causes of hyperprolactinemia, because hyperprolactinemia may be 
due to a reason of concomitant disease, but not proved the cause-relationship to PCOS. 
Treatment of infertility associated with PCOS has changed in the last decade due to the 
introduction of new medications such as insulin-sensitizing drugs, aromatase inhibitors, 
gonadotropin treatment etc. (Bracero 2001, Urman, 2006, Escobar-Morreale, 2004) 
 In a study conducted in Brazil, among the 82 PCOS women, 13 (16%) presented high 
PRL levels (over 100 microg/l). There were several reasons of hyperprolactinemia: 
pituitary adenoma; drug-induced hyperprolactinemia, or macroprolactinemia. The non-
hyperprolactinemic PCOS patients (over 80%) represented normal PRL levels. The 
authors concluded that hyperprolactinemia is not a clinical manifestation of PCOS. 
(Filho, 2007) 
4.5. Medications 
Some medications can cause higher levels of prolactin to be produced. The most common 
medications that do this are known as anti-psychotic medications. The antipsychotics mostly 
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act as dopaminergic neurotransmitters/ receptor blockers can also cause endocrine side 
effects, as hyperprolactinaemia and it is most common side effect of first-generation 
antipsychotics. The second- and thirdgeneration antipsychotics have a weaker affinity for 
D2 dopamine receptors, thus hyperprolactinemia is less common when such medication is 
used. (Uzun et al. 2005). The risk of side effects caused by antipsychotics is individual and it 
does not depend solely on the therapeutic dose and may have influence on some 
predisposing conditions. (Ružić 2011) 
Other medications which may increase prolactin levels: 
 Some types of anti-depressants, serotonin reuptake inhibitors, SRIs (fluvoxamine; 
fluoxetine; paroxetine, duloxetine etc) 
 Some types of sedatives 
 Catecholamine depletor 
 Dopamine synthesis inhibitor 
 Neuropeptides 
 Anticonvulsants 
 Opiates and opiate antagonists 
 Estrogen Oral contraceptives (birth control pills) 
 Some types of blood pressure medications (methyldopa, verapamil) 
 A medication for nausea (Reglan, metoclopramide) 
 Antacids (cimetidine) 
4.6. Stress 
A high prolactin level can sometimes be related to physical stress. Even drawing blood can 
by itself cause someone to produce and immediate prolactin-release. PRL eleveation can also 
detected in response to strong or sudden external stimuli in general, such as stressful 
environmental conditions, or can be related to physchological reasons. This latter can be 
evaluated by stress profile or measured by experimental conditions, such as “Screamer 
Index”, which is shown resulting in values to be parallel to levels of hyperprolactinemia in 
women. (Harrison, 1988; Cepisky, 1992). On the other hand, anxiety and irritability maybe a 
result of hyperprolactinemia. In rat models PRL increased the stimulatory effect of ACTH-
induced corticosterone secretion (Jaroenporn, 2007).  
 Endocrine abnormalities are frequently associated with a wide range of psychological 
symptoms. These symptoms may reach the level of psychiatric illness (mainly mood 
and anxiety disorders) or just being identified by the subclinical forms of assessment 
provided by the Diagnostic Criteria for Psychosomatic Research (DCPR). In a 
population study reported by Sonino et al, (2007), the majority of patients suffered from 
at least one of the three DCPR syndromes considered: irritable mood (over 45%), 
demoralization, persistent somatization. Long-standing endocrine disorders may imply 
a degree of irreversibility of the pathological process. Endocrine treatment may cause 
even the worsening of psychological symptoms. The methodology and assessment 
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score provided by DCPR tests have been demonstrated to be a valuable tool for 
psychological assessment in endocrine disease from diagnostic to follow-up periods. 
(Sonino 2007) 
 In clinical environment the variability of PRL concentration in random estimations 
underline the need for special testing to rule out stress-related hyperprolactinemia and 
diagnostic pitfalls. It was recommended by the results, that two or three serial PRL 
determinations in resting conditions provide more reliable results (Muneyyirci-Delale, 
1989). 
 In experimental conditions, hyperprolactinemia and stress interact differentially 
according to the length of the stimuli and that is connected to the immune response 
modulated by PRL. Surgical or restraint stress induce marked (2x- 4x) increase of 
plasma PRL of control rats, but interestingly did not change the PRL levels of 
hyperprolactinemic rats. In both cases the plasma glucose levels reported elevated 
(Reis, 1996). 
 It is suggested as a result of a retrospective observational study, that life events such as 
changes in subject’s social or personal environment indicated that these stressful 
conditions may provoke hyperprolactinemia. Even an exposure during childhood to a 
stressful environment maybe associated with hyperprolactinemia and/or galactorrhea 
later in life as a response to specific environmental changes (Sobrinho, 1984). Patients 
with hyperprolactinemia reported significantly more life events, these events rated as 
being of „moderate”, marked or severe „negative” impact compared with control 
subjects (Sonino, 2004).  
 There is evidence that several external stress-factors may contribute to the occurrence of 
hyperprolactinemia. In theory, stress might have been involved in facilitation of a clonal 
proliferation of a single mutated cell and cause prolactinomas. Patients in functional 
hyperprolactinemic status, stress might trigger neuroendocrine changes involving DA 
and/or serotonin, which both can consequently affect PRL release. (Verhelst, 2003; 
Freeman, 2000; Fava, 1981.) 
5. Hyperprolactinemia and infertility 
Prolactin is a pituitary-derived hormone that plays an important role in a variety of 
reproductive functions. It is an essential factor for normal production of breast milk 
following childbirth. Additionally, prolactin negatively modulates the secretion of pituitary 
hormones responsible for gonadal function, including luteinizing hormone and follicle-
stimulating hormone. Clnincally significant hyperprolactinemia may result in 
hypogonadism, infertility, and galactorrhea, or in some cases it may remain asymptomatic 
for a long period. (Klibanski 2010) The most commonly cited indications for treatment of 
microprolactinomas is infertility and hypogonadism. Hypogonadism and infertility 
associated closely with the treatment: DA agonists can restore normal PRL levels and 
consequently the normal gonadal function . According to the date of a meta-analyis, patients 
treated with bromocriptine had normalization of prolactin levels and it was successful in 
53% of patients with infertility. Studies with cabergoline showed similar results: cabergoline 
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was shown more effective than bromocriptine reducing PRL levels, or in symptoms of 
amenorrhea/oligomenorrhea, or in some of the patient-important outcomes. (Gillam 2006; 
Wang 2012)  
Prolactin is under dual regulation by hypothalamic hormones delivered through the 
hypothalamic–pituitary portal circulation. The differential diagnosis and causes of 
pathological hyperprolactinemia are summarized in Figure 1. 
The predominant signal is inhibitory, preventing prolactin release, and is mediated by the 
neurotransmitter dopamine. The stimulatory signal is mediated by the hypothalamic TRH. 
The balance between the two opposite signals determines the amount of prolactin released 
from the anterior pituitary gland (Verhelst; 2003). 
 
 
 
Figure 1. Prolactin is under dual control from the hypothalamus. 
6. Hyperprolactinemia management  
 The first steps in cases of signs of hyperprolactinemia should be a critical diagnosis, as 
discussed above, may involve dynamic testings, assessment for macroprolactinemia 
and further laboratory tests to eliminate false positive or negative results. 
Anterior pituitary lobe 
Prolactin production 
Dopamine TRH 
+ _ 
Medications 
Neuroleptics: phenothiazines, haloperidol 
Antihypertensives: calcium-channel blockers, 
Psychotropic agents: tricyclic antidepressants 
Anti-ulcer agents: H2 antagonists 
Opiates 
Hypothalamic PRL stimulation 
Primary hypothyroidism 
Adrenal insufficiency 
Neurogenic 
Chest-wall injury 
Breast stimulation 
Breast-feeding 
Physiologic causes 
Pregnancy 
Estrogen 
Reduced PRL elimination 
Renal failure 
Hepatic insufficiency 
Macroprolactinemia 
Increased PRL production 
Ovarian: polycystic ovarian syndrome 
Pituitary tumours: 
Adenomas 
Hypothalamic stalk interruption 
Hypophysitis (inflammation) 
+ 
+ 
+ 
+ 
+ 
+ 
_
_ 
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 Consider other underlying causes, such as suspected drug-induced hyperprolactinemia, 
hypothyroidism, elimination/renal failure, other persistent pituitary and parasellar 
tumours, etc. 
 Identify the size of pituitary tumour and other anatomical circumstances. 
 Apply pharmacotherapy treatment specified to patient 
The major steps of diagnosis of hyperprolactinemia is summarized in Figure 2.  
 
 
 
Figure 2. Approach to diagnosis of hyperprolactinemia. 
7. Recommendations for the diagnosis of hyperprolactinemia  
Specific recommendations for diagnosis of hyperprolactinemia include the following 
(Melmed 2011): 
 A single measurement of serum prolactin level can confirm the diagnosis if the level is 
above the upper limit of normal and the serum sample was obtained without excessive 
venipuncture stress. Dynamic testing of prolactin secretion is not recommended to 
diagnose hyperprolactinemia. 
 Macroprolactin evaluation is recommended in patients with asymptomatic 
hyperprolactinemia. 
 When there is a discrepancy between a very large pituitary tumour and a mildly 
elevated prolactin level, serial dilution of serum samples is recommended to eliminate 
the "hook effect," or an artifact that can occur with some immunoradiometric assays 
leading to a falsely low prolactin value. 
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8. Recommendations for drug-induced hyperprolactinemia 
Specific recommendations for management of drug-induced hyperprolactinemia are as 
follows (Melmed 2011): 
 In a symptomatic patient with suspected medication-induced hyperprolactinemia, the 
drug should be discontinued for 3 days or an alternative drug substituted, and the 
serum prolactin measurement should then be repeated. However, the patient's 
physician should be consulted before an antipsychotic agent is discontinued or 
substituted. If the drug cannot be discontinued and the onset of the hyperprolactinemia 
does not coincide with starting therapy, magnetic resonance imaging (MRI) of the 
pituitary gland may distinguish medication-induced hyperprolactinemia from 
symptomatic hyperprolactinemia caused by a pituitary or hypothalamic mass. 
 Patients with asymptomatic medication-induced hyperprolactinemia should not be 
treated. Estrogen or testosterone can be used in patients with long-term hypogonadism 
(hypogonadal symptoms or low bone mass) caused by medication-induced 
hyperprolactinemia. 
 If it is not possible to stop the drug causing medication-induced hyperprolactinemia, 
cautious administration of a dopamine agonist should be considered, in consultation 
with the patient's physician. 
9. Treatment of hyperprolactinemia 
As noted above, prolactin levels can often be corrected by stopping suspected medication or 
switching to a different medication type. Correction of hypothyroidism is also effective and 
specific to reduce PRL levels. If prolactin levels are persistently high, they can be effectively 
treated with a group of medications known as dopamine agonists. 
According to our clinical practice patients with macroadenoma suggested to undergo 
transsphenoidal pituitary surgery. Medical treatment is given to the subjects with 
microadenoma, persistent postoperative hyperprolactinemia, and to those cases of 
hyperprolactinemia when it is caused by other medications.  
From the available mediactions Bromocriptine 2.5 mg (Parlodel®, Novartis) once or twice a 
day or cabergoline 0.5 mg (Dostinex®, Pharmacia) once or twice a week is given as 
prolactin-lowering drug. 
9.1. Bromocriptine (Parlodel) 
Parlodel is an effective and inexpensive medication for high prolactin levels. Parlodel is 
usually taken at bedtime with a snack. This is because Parlodel will occasionally cause 
dizziness or stomach upset, so taking it before sleep and with food will reduce those side 
effects. Generally with time, the side effects stop anyway.  
The prolactin levels can be rechecked in about three weeks. If the levels are still elevated the 
dose can be increased or a different medication can be tried. The administration of Parlodel 
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can be stopped upon diagnosis of pregnancy. However, if a woman has a macroadenoma, 
Parlodel should be continued through pregnancy and delivery. 
Due to the side effects, some women can not tolerate Parlodel. For these women, they may 
try alternatives, e.g. vaginal bioadhesive suppositories or inserted the pills vaginally instead 
of taking them orally.  
9.2. Cabergoline (Dostinex) 
Because it is more expensive, cabergoline is not usually the first choice for treatment of high 
prolactin levels. It is usually used when Parlodel is ineffective or a woman cannot tolerate 
the side effects. Cabergoline is a longer acting medication. It is usually given twice a week 
instead of every day. 
The Endocrine Society has released a new clinical practice guideline for the diagnosis and 
treatment of patients with hyperprolactinemia (Melmed, 2011). The new recommendations 
for management of elevated levels of the PRL, which is associated with infertility, low sex 
drive, and bone loss, are listed. 
10. Recommendations for the treatment of prolactinoma 
Specific recommendations for management of prolactinoma are as follows (Melmed 2011):: 
 Dopamine agonist therapy is recommended to reduce prolactin levels and tumor size 
and to restore gonadal function in patients with symptomatic prolactin-secreting 
microadenomas or macroadenomas. Compared with other dopamine agonists, 
cabergoline is more effective in normalizing prolactin levels and in shrinking pituitary 
tumours. 
 Dopamine agonists are not recommended for asymptomatic patients with 
microprolactinomas. However, patients with microadenomas who have amenorrhea 
can be treated with a dopamine agonist or oral contraceptives. 
 In patients treated with dopamine agonists for at least 2 years who no longer have 
elevated serum prolactin levels or visible tumour on MRI, careful clinical and 
biochemical follow-up therapy may be tapered and perhaps discontinued. 
11. Recommendations for resistant, malignant prolactinoma 
Specific recommendations for management of resistant and malignant prolactinoma are as 
follows (Melmed 2011): 
 For symptomatic patients in whom normal prolactin levels are not achieved or who 
have significant shrinking of the tumour size while receiving standard doses of a 
dopamine agonist, the dose should be increased rather than referring the patient for 
surgery. 
 Patients resistant to bromocriptine should be switched to cabergoline. 
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 Symptomatic patients with prolactinomas who cannot tolerate high doses of 
cabergoline or who are unresponsive to dopamine agonist therapy should be offered 
trans-sphenoidal surgery. Patients intolerant of oral bromocriptine may respond to 
intravaginal administration. Radiation therapy is recommended for patients in whom 
surgical treatment fails or for those with aggressive or malignant prolactinomas. 
 Temozolomide therapy is recommended for patients with malignant prolactinomas. 
12. Recommendations for pregnant women with prolactinoma 
Specific recommendations for management of prolactinoma during pregnancy are as 
follows (Melmed 2011): 
 Women with prolactinomas should discontinue dopamine agonist therapy as soon as 
pregnancy is recognized, except for selected patients with invasive macroadenomas or 
adenomas abutting the optic chiasm. 
 Serum prolactin measurements should not be performed during pregnancy. 
 Unless there is clinical evidence for tumour growth, such as visual field impairment, 
routine use of pituitary MRI during pregnancy is not recommended in patients with 
microadenomas or intrasellar macroadenomas. 
 Women with macroprolactinomas that do not shrink during dopamine agonist therapy 
or women who cannot tolerate bromocriptine or cabergoline should be counselled 
regarding the potential benefits of surgical resection before attempting pregnancy. 
 Pregnant women with prolactinomas who experience severe headaches and/or visual 
field changes should have formal visual field assessment followed by MRI without 
gadolinium. 
 Bromocriptine therapy is recommended in patients who experience symptomatic 
growth of a prolactinoma during pregnancy. 
Hyperprolactinemia has been proposed to block ovulation through inhibition of GnRH 
release. Kisspeptin neurons, which express prolactin receptors, were recently identified as 
major regulators of GnRH neurons. A recently published study demonstrated 
that hyperprolactinemia in mice induced anovulation, reduced GnRH and gonadotropin 
secretion, and diminished kisspeptin expression. Kisspeptin administration restored 
gonadotropin secretion and ovarian cyclicity, suggesting that kisspeptin neurons play a 
major role in hyperprolactinemic anovulation. This study indicate that administration of 
kisspeptin may serve as an alternative therapeutic approach to restore the fertility of 
hyperprolactinemic women who are resistant or intolerant to dopamine agonists (Sonigo, 
2012). 
To sum up, the systematic reviews and meta-analyses affirm the use of dopamine agonists 
in treating hyperprolactinemia and reducing associated morbidity. Cabergoline was found 
to be more effective than bromocriptine in achieving normoprolactinemia and resolving 
amenorrhea/oligomenorrhea and galactorrhea. Radiotherapy and surgery are efficacious in 
patients with resistance or intolerance to dopamine agonists (Wang, 2012). 
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13. Summary 
Hyperprolactinemia is defined as higher-than-normal blood levels of the hormone prolactin. 
This hormone is made by the pituitary gland, which is located at the base of the brain. The 
main function of prolactin is to stimulate breast milk production after childbirth. High 
prolactin levels are normal during pregnancy and breastfeeding. In other cases, prolactin 
can become too high because of a disease or the use of certain medications. Often, the cause is 
a prolactin-producing tumour in the pituitary gland, called a prolactinoma. This tumour is 
mostly benign (adenomas), meaning not invasive (invasive tumours with multiple recurrences 
are “atypical adenomas”), and not metastatic (malignant tumours, carcinomas). It is more 
common in women than men. Rarely, children and adolescents develop prolactinomas. Other 
brain tumours may also cause the pituitary gland to make too much prolactin. 
Prolactin-secreting pituitary tumours are a common cause of amenorrhea and infertility in 
premenopausal women. The goals of therapy are to normalize prolactin, restore gonadal 
function and fertility, and reduce tumour size, and dopamine agonists are the preferred 
therapy. Clinically significant tumour enlargement during pregnancy is uncommon and 
dependent on tumour size and pre-pregnancy treatment. 
Accroding to over 180 clinical study reports (across 3000 patients) treatment with 
bromocriptine or with cabergoline are both effective in normalization of prolactin levels and 
also successful in restoration of fertility over 53% of patients. Cabergoline was shown more 
effective than bromocriptine in persistent hyperprolactinemia, and reducing the symptoms 
of amenorrhea/oligomenorrhea. At our institution patients with symptomatic 
prolactinomas, both micro- and macroadenomas, are treated with cabergoline as the first-
line approach. In the small group of patients who do not respond to this treatment, or who 
refuse long-term therapy, surgery is offered. Radiotherapy is given if both pharmacologic 
therapy and surgery fail. 
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